Macular Degeneration

What exactly is macular degeneration?

Macular degeneration is the most common cause of loss of central vision in people over 60 years of age. In this disease there is a decrease in central vision, because the macula, which is the sensitive central area of ​​the ocular humor, is affected.

There are two types of macular degeneration: dry and wet .

Macular degeneration of the dry type, is gradual and there is no cure for it. It is recommended to support the function of the eye with vitamins and to avoid smoking. Approximately 10% of those affected will transform to the neovascular wet form of the disease, a clinically more aggressive and destructive, yet more amenable to treatment.

In wet macular degeneration, the decrease in vision is abrupt and accompanied by bleeding in the macula.

What is the treatment of macular degeneration?

Today’s treatment involves the injection of specialized medication into the eye (intraocular injections) every 1 or 2 months.

ORAYA iRAY is a new, revolutionary, non invasive method for treating the age-related wet macular macular degeneration, recently acquired by ZEISS.

The rapid expansion of treatment is due to its impressive results: In patients with active disease it reduces the number of injections needed by 45%, while maintaining visual acuity, 1 in 4 patients did not need any other injection.

ORAYA treatment has been successfully applied for three years in patients in Switzerland, Germany and selected public hospitals in the UK National Healthcare System (NHS).

The treatment is supported by a specialized team of medical scientists with long-term experience abroad and in Greece.

After the treatment, in the same day, patient can return to his home.

The scope of the procedure is to improve vision while at the same time reducing the number of anti-angiogenic (anti-VEGF) injections required.

The 30 – 60 minute non-invasive treatment takes place in a single session.

It has the potential to selectively affect and inhibit the growth of neo vascularizations responsible for macular degeneration of the wet type.

At the same time it reduces the inflammation and the possibility of scarring in the macula, a frequent phenomenon in these cases.

Operating mechanism

The new innovative IRay stereotactic irradiation system, through which ORAYA treatment is applied to the macula, utilizes low energy X-rays, high precision targeting through a robotic system, with a particularly fine 4mm beam.

Our highly trained team of scientists, using high-tech software and specially configured computer program succeeds:

• To precisely target the affected area in the macula, while at the same time maximally protecting the adjacent healthy tissue.

• Continuous monitoring of eye movement resulting in a high-precision therapeutic band (Real Time Gating).


How big is the dose taken during ORAYA treatment?

Although the dose received by the macula is relatively high, the dose absorbed by the body is very low in proportion to 1/10 of an X-ray.

• Has someone lost due to the treatment ORAYA his vision?

It does not cause cataracts or other side effects in the eye,
No reductions in vision have been recorded so far as a result of ORAYA treatment.

When will I return to my normal activities?

Your usual activities will not be restricted by treatment. Your doctor will give you further specific instructions.

Clinical Research

For more than five years, of research and development, ORAYA has undergone thorough testing and clinical trials, and has proven its efficacy and effectiveness based on the well-designed INTREPID clinical study published in the prestigious Ophthalmology journal.

The Scientific Team

  • Emmanouil A. Lazaridis BSc, MSc, PhD, MD, MBA, Medical Physicist – Department Head
  • George Katiniotis MD, Radiation Oncologist – Scientific Advisor
  • George Kampougeris MD, MRCSEd, PhD,Consultant Ophthalmic Surgeon – Scientific Advisor – Director of Medical Retina Department
  • Panos Masaoutis MD, Phd, MRCOphth, MRCSEd(Ophth), ICO, Consultant Ophthalmic Surgeon – Medical Retina Specialist
  • Petros Aristodemou BSc, MBBS, FRCOphth (London) – Centre for the management of diseases of the vitreous, retina & maculaVitreous Retina Macula Consultants Of Cyprus
  • Stelios Nikoletopoulos BSc, MSc, Medical Physicist

Would you need any further information? CONTACT US